Review



apatinib  (MultiTarget Pharmaceuticals)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    MultiTarget Pharmaceuticals apatinib
    Apatinib, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/apatinib/product/MultiTarget Pharmaceuticals
    Average 90 stars, based on 1 article reviews
    apatinib - by Bioz Stars, 2026-02
    90/100 stars

    Images



    Similar Products

    apatinib  (MedChemExpress)
    96
    MedChemExpress apatinib
    ( A–C ) Metabric database analysis in BCIP revealed high expression levels of STAMBPL1, FOXO1, and GRHL3 in TNBC ( n = 319) compared with non-TNBC ( n = 1661). ( D ) The effect of STAMBPL1 overexpression in HCC1806 cells was detected by Western blotting. ( E ) Nude mice with tumors received the FOXO1 <t>inhibitor</t> <t>AS1842856</t> (10 mg/kg, every 2 days) or the VEGFR inhibitor <t>Apatinib</t> (50 mg/kg, every 2 days) or a combination of both treatments. The effect of the drug treatments on the transplanted tumors was assessed by imaging the tumors. ( F, G ) The weight and growth of the transplanted tumors in the nude mice were statistically analyzed. The vector control group and the STAMBPL overexpression group were compared. The nondrug group and the combined drug group in the vector control group were compared. The nondrug group and the combined drug group in the STAMBPL overexpression group were compared (n = 8). ( H ) The final weights of the nude mice were statistically analyzed (n = 4). Mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001, t- test. Figure 8—source data 1. PDF file containing original western blots for , indicating the relevant bands and treatments. Figure 8—source data 2. Original files for western blot analysis displayed in .
    Apatinib, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/apatinib/product/MedChemExpress
    Average 96 stars, based on 1 article reviews
    apatinib - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier
    apatinib  (Jiangsu Hengrui Medicine)
    90
    Jiangsu Hengrui Medicine apatinib
    ( A–C ) Metabric database analysis in BCIP revealed high expression levels of STAMBPL1, FOXO1, and GRHL3 in TNBC ( n = 319) compared with non-TNBC ( n = 1661). ( D ) The effect of STAMBPL1 overexpression in HCC1806 cells was detected by Western blotting. ( E ) Nude mice with tumors received the FOXO1 <t>inhibitor</t> <t>AS1842856</t> (10 mg/kg, every 2 days) or the VEGFR inhibitor <t>Apatinib</t> (50 mg/kg, every 2 days) or a combination of both treatments. The effect of the drug treatments on the transplanted tumors was assessed by imaging the tumors. ( F, G ) The weight and growth of the transplanted tumors in the nude mice were statistically analyzed. The vector control group and the STAMBPL overexpression group were compared. The nondrug group and the combined drug group in the vector control group were compared. The nondrug group and the combined drug group in the STAMBPL overexpression group were compared (n = 8). ( H ) The final weights of the nude mice were statistically analyzed (n = 4). Mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001, t- test. Figure 8—source data 1. PDF file containing original western blots for , indicating the relevant bands and treatments. Figure 8—source data 2. Original files for western blot analysis displayed in .
    Apatinib, supplied by Jiangsu Hengrui Medicine, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/apatinib/product/Jiangsu Hengrui Medicine
    Average 90 stars, based on 1 article reviews
    apatinib - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    apatinib  (MultiTarget Pharmaceuticals)
    90
    MultiTarget Pharmaceuticals apatinib
    ( A–C ) Metabric database analysis in BCIP revealed high expression levels of STAMBPL1, FOXO1, and GRHL3 in TNBC ( n = 319) compared with non-TNBC ( n = 1661). ( D ) The effect of STAMBPL1 overexpression in HCC1806 cells was detected by Western blotting. ( E ) Nude mice with tumors received the FOXO1 <t>inhibitor</t> <t>AS1842856</t> (10 mg/kg, every 2 days) or the VEGFR inhibitor <t>Apatinib</t> (50 mg/kg, every 2 days) or a combination of both treatments. The effect of the drug treatments on the transplanted tumors was assessed by imaging the tumors. ( F, G ) The weight and growth of the transplanted tumors in the nude mice were statistically analyzed. The vector control group and the STAMBPL overexpression group were compared. The nondrug group and the combined drug group in the vector control group were compared. The nondrug group and the combined drug group in the STAMBPL overexpression group were compared (n = 8). ( H ) The final weights of the nude mice were statistically analyzed (n = 4). Mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001, t- test. Figure 8—source data 1. PDF file containing original western blots for , indicating the relevant bands and treatments. Figure 8—source data 2. Original files for western blot analysis displayed in .
    Apatinib, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/apatinib/product/MultiTarget Pharmaceuticals
    Average 90 stars, based on 1 article reviews
    apatinib - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    apatinib jiangsu hengrui co  (Jiangsu Hengrui Medicine)
    90
    Jiangsu Hengrui Medicine apatinib jiangsu hengrui co
    ( A–C ) Metabric database analysis in BCIP revealed high expression levels of STAMBPL1, FOXO1, and GRHL3 in TNBC ( n = 319) compared with non-TNBC ( n = 1661). ( D ) The effect of STAMBPL1 overexpression in HCC1806 cells was detected by Western blotting. ( E ) Nude mice with tumors received the FOXO1 <t>inhibitor</t> <t>AS1842856</t> (10 mg/kg, every 2 days) or the VEGFR inhibitor <t>Apatinib</t> (50 mg/kg, every 2 days) or a combination of both treatments. The effect of the drug treatments on the transplanted tumors was assessed by imaging the tumors. ( F, G ) The weight and growth of the transplanted tumors in the nude mice were statistically analyzed. The vector control group and the STAMBPL overexpression group were compared. The nondrug group and the combined drug group in the vector control group were compared. The nondrug group and the combined drug group in the STAMBPL overexpression group were compared (n = 8). ( H ) The final weights of the nude mice were statistically analyzed (n = 4). Mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001, t- test. Figure 8—source data 1. PDF file containing original western blots for , indicating the relevant bands and treatments. Figure 8—source data 2. Original files for western blot analysis displayed in .
    Apatinib Jiangsu Hengrui Co, supplied by Jiangsu Hengrui Medicine, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/apatinib jiangsu hengrui co/product/Jiangsu Hengrui Medicine
    Average 90 stars, based on 1 article reviews
    apatinib jiangsu hengrui co - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    apatinib  (Selleck Chemicals)
    93
    Selleck Chemicals apatinib
    ( A–C ) Metabric database analysis in BCIP revealed high expression levels of STAMBPL1, FOXO1, and GRHL3 in TNBC ( n = 319) compared with non-TNBC ( n = 1661). ( D ) The effect of STAMBPL1 overexpression in HCC1806 cells was detected by Western blotting. ( E ) Nude mice with tumors received the FOXO1 <t>inhibitor</t> <t>AS1842856</t> (10 mg/kg, every 2 days) or the VEGFR inhibitor <t>Apatinib</t> (50 mg/kg, every 2 days) or a combination of both treatments. The effect of the drug treatments on the transplanted tumors was assessed by imaging the tumors. ( F, G ) The weight and growth of the transplanted tumors in the nude mice were statistically analyzed. The vector control group and the STAMBPL overexpression group were compared. The nondrug group and the combined drug group in the vector control group were compared. The nondrug group and the combined drug group in the STAMBPL overexpression group were compared (n = 8). ( H ) The final weights of the nude mice were statistically analyzed (n = 4). Mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001, t- test. Figure 8—source data 1. PDF file containing original western blots for , indicating the relevant bands and treatments. Figure 8—source data 2. Original files for western blot analysis displayed in .
    Apatinib, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/apatinib/product/Selleck Chemicals
    Average 93 stars, based on 1 article reviews
    apatinib - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    apatinib mesylate  (Jiangsu Hengrui Medicine)
    90
    Jiangsu Hengrui Medicine apatinib mesylate
    ( A–C ) Metabric database analysis in BCIP revealed high expression levels of STAMBPL1, FOXO1, and GRHL3 in TNBC ( n = 319) compared with non-TNBC ( n = 1661). ( D ) The effect of STAMBPL1 overexpression in HCC1806 cells was detected by Western blotting. ( E ) Nude mice with tumors received the FOXO1 <t>inhibitor</t> <t>AS1842856</t> (10 mg/kg, every 2 days) or the VEGFR inhibitor <t>Apatinib</t> (50 mg/kg, every 2 days) or a combination of both treatments. The effect of the drug treatments on the transplanted tumors was assessed by imaging the tumors. ( F, G ) The weight and growth of the transplanted tumors in the nude mice were statistically analyzed. The vector control group and the STAMBPL overexpression group were compared. The nondrug group and the combined drug group in the vector control group were compared. The nondrug group and the combined drug group in the STAMBPL overexpression group were compared (n = 8). ( H ) The final weights of the nude mice were statistically analyzed (n = 4). Mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001, t- test. Figure 8—source data 1. PDF file containing original western blots for , indicating the relevant bands and treatments. Figure 8—source data 2. Original files for western blot analysis displayed in .
    Apatinib Mesylate, supplied by Jiangsu Hengrui Medicine, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/apatinib mesylate/product/Jiangsu Hengrui Medicine
    Average 90 stars, based on 1 article reviews
    apatinib mesylate - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    ( A–C ) Metabric database analysis in BCIP revealed high expression levels of STAMBPL1, FOXO1, and GRHL3 in TNBC ( n = 319) compared with non-TNBC ( n = 1661). ( D ) The effect of STAMBPL1 overexpression in HCC1806 cells was detected by Western blotting. ( E ) Nude mice with tumors received the FOXO1 inhibitor AS1842856 (10 mg/kg, every 2 days) or the VEGFR inhibitor Apatinib (50 mg/kg, every 2 days) or a combination of both treatments. The effect of the drug treatments on the transplanted tumors was assessed by imaging the tumors. ( F, G ) The weight and growth of the transplanted tumors in the nude mice were statistically analyzed. The vector control group and the STAMBPL overexpression group were compared. The nondrug group and the combined drug group in the vector control group were compared. The nondrug group and the combined drug group in the STAMBPL overexpression group were compared (n = 8). ( H ) The final weights of the nude mice were statistically analyzed (n = 4). Mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001, t- test. Figure 8—source data 1. PDF file containing original western blots for , indicating the relevant bands and treatments. Figure 8—source data 2. Original files for western blot analysis displayed in .

    Journal: eLife

    Article Title: STAMBPL1 activates the GRHL3/HIF1A/VEGFA axis through interaction with FOXO1 to promote angiogenesis in triple-negative breast cancer

    doi: 10.7554/eLife.102433

    Figure Lengend Snippet: ( A–C ) Metabric database analysis in BCIP revealed high expression levels of STAMBPL1, FOXO1, and GRHL3 in TNBC ( n = 319) compared with non-TNBC ( n = 1661). ( D ) The effect of STAMBPL1 overexpression in HCC1806 cells was detected by Western blotting. ( E ) Nude mice with tumors received the FOXO1 inhibitor AS1842856 (10 mg/kg, every 2 days) or the VEGFR inhibitor Apatinib (50 mg/kg, every 2 days) or a combination of both treatments. The effect of the drug treatments on the transplanted tumors was assessed by imaging the tumors. ( F, G ) The weight and growth of the transplanted tumors in the nude mice were statistically analyzed. The vector control group and the STAMBPL overexpression group were compared. The nondrug group and the combined drug group in the vector control group were compared. The nondrug group and the combined drug group in the STAMBPL overexpression group were compared (n = 8). ( H ) The final weights of the nude mice were statistically analyzed (n = 4). Mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001, t- test. Figure 8—source data 1. PDF file containing original western blots for , indicating the relevant bands and treatments. Figure 8—source data 2. Original files for western blot analysis displayed in .

    Article Snippet: AS1842856 (Cat#HY-100596) and apatinib (Cat#HY-13342S) were purchased from MCE (New Jersey, USA).

    Techniques: Expressing, Over Expression, Western Blot, Imaging, Plasmid Preparation, Control